Complement Inhibitors Market Size, Share & Industry Analysis, By Drug (Eculizumab, Ravulizumab, Pegcetacoplan, Iptacopan, Sutimlimab, Avacincaptad pegol, & Others), By Disease Indication (PNH, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, Geographic Atrophy, Cold Agglutinin Disease), By Age Group, By Type (Branded, Biosimilar, & Others), By Target Pathway Inhibitors (C5, C3, C1s, Factor B, Factor D, & Others), By Route of Administration, By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail/Online Pharmacies, & Others), & Regional Forecast, 2026-2034

Last Updated: May 04, 2026 | Format: PDF | Report ID: FBI116060

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 15.40% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Region
By Drug	Eculizumab Ravulizumab Pegcetacoplan Iptacopan Sutimlimab Avacincaptad pegol Others
By Disease Indication	Paroxysmal Nocturnal Hemoglobinuria (PNH) Atypical Hemolytic Uremic Syndrome (aHUS) Generalized Myasthenia Gravis Neuromyelitis Optica Spectrum Disorder Geographic Atrophy Cold Agglutinin Disease Others
By Age Group	Pediatric Adults
By Type	Branded Biosimilar Others
By Target Pathway	C5 Inhibitors C3 Inhibitors C1s Inhibitors Factor B Inhibitors Factor D Inhibitors Others
By Route of Administration	Intravenous Subcutaneous Intravitreal Others
By Distribution Channel	Hospital Pharmacies Specialty Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies Others
By Region	North America (By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Country) U.S. Canada Europe (By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug, Disease Indication, Age Group, Type, Target Pathway, Route of Administration, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa